PORRIÑO, SPAIN and Ingelheim, Germany, 21 July, 2016 – CZ Veterinaria (CZV) and Boehringer Ingelheim Animal Health announced today that both companies have entered into a cooperation to provide Entericolix®, an innovative sow vaccine, to the European swine vaccine market. CZV has developed and registered Entericolix® in Europe; Boehringer Ingelheim Animal Health will use its strong swine distribution network and technical support to provide the vaccine to customers.

The European National Authorities have approved Entericolix® which is unique in providing a 21 days duration of immunity against diarrhoea in piglets caused by E. coli. and C. perfringens Type C.

The vaccine reduces mortality and clinical signs caused by E. coli neonatal diarrhoea and Necrotic Enteritis. Entericolix® has the unique claim of extending this protection to piglets until 21 days of age, even after the pigs were weaned. Furthermore, it provides protection against early onset of Oedema Disease caused by F18 E. coli up to 28 days of age (7 days after weaning). Oedema Disease is a naturally occurring post weaning piglet disease seen after infection with certain strains of E. coli that can lead to neurological signs and death.

About CZV
CZV is a biopharmaceutical company focused on the prevention of animal diseases. CZV is a world leader in Mycobacteria production and develops and manufactures a wide range of veterinary vaccines and medicinal products. CZV has its own vaccines distributed by third parties and also develop and manufacture a wide range of biologicas and pharmaceuticals for multinationals and goverments worldwide. Some of the most important CZV production plants are “The Mycobacterium Plant” -the largest in the world for this type of bacteria-, “The Clostridia plant” -the largest of Europe- and the most recent, “The Aerobic Culture Plant”.

About Boehringer Ingelheim Animal Health
Boehringer Ingelheim Animal Health is the 6th largest animal health business in the world and is committed to providing leading innovative solutions to prevent, treat and cure animal diseases. With 3,800 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about € 1.36 billion in 2015, representing 9% of the corporation’s revenue base. Main brands of Boehringer Ingelheim’s Animal Health portfolio are Ingelvac Circoflex® (2015 sales of € 281 million), Metacam® (2015 sales of € 101 million), Ingelvac® PRRS (2015 sales of € 99 million) and Duramune® (2015 sales of € 88 million). The Boehringer Ingelheim Animal Health Business is global leader in swine vaccines and holds strong positions in companion animal and cattle vaccines as well as in pharmaceutical specialties for animal use. The company researches and develops therapeutic solutions for animals in the US, Germany, China, Mexico and Japan. In its research-driven Animal Health business, Boehringer Ingelheim continually invests around 12% of net sales of the Animal Health business in R&D.